EDIT
Editas Medicine, Inc.
$3.04
-0.12 (-3.80%)
At close · Jul 15
Market Cap
$297.15M
Shares
97,906,282
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.04
Open$3.15
Day$2.99–3.17
52W$1.66–4.54
Avg vol 30d2.7M
Short int22.5M · 23.0% float · 7.2d
Short vol63%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
+3%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
48%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+43%
trailing
YTD return
+48%
this year
Relative strength
+33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Distributing
12 of 208 funds reported for Jun 30 · net -258.2K sh shares
Insider flow
Distributing
Net -$44.8K over 90 days · 100% sells
Short interest
Rising
22.95% of float · ▲ +22.0% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
208 holders — mid 3-yr range
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+133%
Y/Y
EPS growth
+38%
Y/Y
Free cash flow
$-165.8M
Balance sheet
$89.2M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
48%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Distributing
12 of 208 funds reported for Jun 30 · net -258.2K sh shares
Insider flow
Distributing
Net -$44.8K over 90 days · 100% sells
Short interest
Rising
22.95% of float · ▲ +22.0% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
208 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $3 · 48%
52-wk high $5
vs 200-day avg +13%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDIT
this stock
Editas Medicine, Inc.
|
$297.15M | +48.3% | +132.6% | — | 23.0% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDIT | -17.2% | +18.3% | +43.4% | -6.2% | +48.3% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -18.4% | +18.5% | +33.3% | -7.3% | +37.6% |
Key facts
CIK
1650664
CUSIP
28106W103
13F (30d)
12 filings
10 filers
Visit website
Investor relations